THE MOLECULAR BIOLOGY OF HUMAN OVARIAN CANCER
Grant number: 1117044 | Funding period: 2017 - 2021
The Fellowship would support Professor Bowtell, one of the world’s leading ovarian cancer researchers. His work focuses on clinical problems of chemotherapy resistance and the development of new therapeutic approaches. His studies are underpinned by the Australian Ovarian Cancer Study (AOCS), one of the world’s most sophisticated clinical cohort studies of ovarian cancer, with over 3000 Australian women enrolled.
Related publications (5)
Evolution of core archetypal phenotypes in progressive high grade serous ovarian cancer.
Aritro Nath, Patrick Cosgrove, Benjamin Copeland, Hoda Mirsafian, Elizabeth Christie, Lance Pflieger, Sumana Majumdar, Mihaela Cristea, Ernest Han, Stephen Lee, Edward Wang, Sian Fereday, Nadia Traficante, Ravi Salgia, Theresa Werner, Adam Cohen, Phillip Moos, Jeffrey Chang, David Bowtell, Andrea Bild
The evolution of resistance in high-grade serous ovarian cancer (HGSOC) cells following chemotherapy is only partially understood...
Noncanonical IL6 Signaling-Mediated Activation of YAP Regulates Cell Migration and Invasion in Ovarian Clear Cell Cancer
Walid J Azar, Elizabeth L Christie, Chris Mitchell, David S Liu, George Au-Yeung, David DL Bowtell
Ovarian clear cell adenocarcinoma (OCCA) is characterized by a particularly poor response to conventional chemotherapy and a short..
Pooled Genomic Screens Identify Anti-apoptotic Genes as Targetable Mediators of Chemotherapy Resistance in Ovarian Cancer
Elizabeth H Stover, Maria B Baco, Ofir Cohen, Yvonne Y Li, Elizabeth L Christie, Mukta Bagul, Amy Goodale, Yenarae Lee, Sasha Pantel, Matthew G Rees, Guo Wei, Adam G Presser, Maya K Gelbard, Weiqun Zhang, Ioannis K Zervantonakis, Patrick D Bhola, Jeremy Ryan, Jennifer L Guerriero, Joan Montero, Felice J Liang
High-grade serous ovarian cancer (HGSOC) is often sensitive to initial treatment with platinum and taxane combination chemotherapy..
Survival Following Chemotherapy in Ovarian Clear Cell Carcinoma Is Not Associated with Pathological Misclassification of Tumor Histotype
Masataka Takenaka, Martin Kobel, Dale W Garsed, Sian Fereday, Ahwan Pandey, Dariush Etemadmoghadam, Joy Hendley, Ayako Kawabata, Daito Noguchi, Nozomu Yanaihara, Hiroyuki Takahashi, Takako Kiyokawa, Masahiro Ikegami, Hirokuni Takano, Seiji Isonishi, Kazuhiko Ochiai, Nadia Traficante, Sreeja Gadipally, Timothy Semple, Dane Vassiliadis
PURPOSE: Although ovarian clear cell carcinomas (OCCC) are commonly resistant to platinum-based chemotherapy, good clinical outcom..
Going to extremes: determinants of extraordinary response and survival in patients with cancer
Flurina AM Saner, Alan Herschtal, Brad H Nelson, Anna deFazio, Ellen L Goode, Susan J Ramus, Ahwan Pandey, Jessica A Beach, Sian Fereday, Andrew Berchuck, Stephanie Lheureux, Celeste Leigh Pearce, Paul D Pharoah, Malcolm C Pike, Dale W Garsed, David DL Bowtell
Research into factors affecting treatment response or survival in patients with cancer frequently involves cohorts that span the m..